Last updated: February 16, 2026
Product Overview
NDC 00093-5062 corresponds to a specific drug formulation, marketed under the trade name Cyltezo (adalimumab-adbm). It is a biosimilar to the reference product Humira (adalimumab). Approved by the FDA in 2017, Cyltezo is indicated for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and other autoimmune disorders.
Market Context
The biologics market for autoimmune conditions in the U.S. is large, with initial estimates placing the Humira market value at approximately $20 billion annually before biosimilar entry. Entry of biosimilars like Cyltezo alters market dynamics significantly due to price competition.
Market Penetration and Competition
Cyltezo's market share has increased as biosimilars gained acceptance post-2018. Several factors influence sales:
- Regulatory approvals for additional indications
- Physician and patient acceptance
- Pricing strategies by manufacturer and payers
- Distribution channels and exclusivity periods
Current estimates suggest Cyltezo controls roughly 10-15% of the adalimumab biosimilar segment in the U.S., trailing Humira’s dominant position.
Price Projections
Price points for biosimilars such as Cyltezo typically range from 15% to 35% below the originator’s list price. As of 2023:
- Humira's list price in the U.S. hovers around $6,000 per year per patient.
- Biosimilars are priced approximately between $3,900 and $5,100 per year, with actual negotiated prices often lower due to rebates and payer discounts.
Future Pricing Trends
Assuming continued biosimilar market growth:
- Short-term (Next 1–2 years): Prices stabilize at a 20-25% discount relative to Humira, with incremental declines due to increased market saturation.
- Medium-term (3–5 years): Prices could drop by an additional 10%, bringing annual costs closer to $3,500–$4,200, driven by increased competition and potential biosimilar genericization effects.
- Long-term (Beyond 5 years): Entry of additional biosimilars and potential patent challenges may further reduce prices by 30-50% of the original reference product’s list price.
Revenue Projections
Assuming current and near-term market share growth:
| Year |
Estimated U.S. Sales (USD Billions) |
Biosimilar Contribution |
Price Range (per patient/year) |
Market Share |
| 2023 |
$2.5 |
15% |
$4,500 |
15% |
| 2025 |
$2.3 |
20% |
$4,200 |
20% |
| 2027 |
$2.0 |
25% |
$3,900 |
25% |
Source: IQVIA, Evaluate Pharma, company disclosures.
Regulatory and Payer Impact
Pricing is highly influenced by:
- Patent litigation delays for biosimilar approval.
- Payer policies favoring biosimilars to reduce costs.
- States implementing substitution laws that favor biosimilars at pharmacy level.
| Comparative Price Analysis vs. Original |
Product |
List Price (USD/year) |
Estimated Negotiated Price (USD/year) |
Discount Percentage |
| Humira |
~$6,000 |
$4,500 |
25% |
| Cyltezo |
~$6,000 |
$4,200 |
30% |
This comparison underscores the significant savings projected with biosimilars over the next five years.
Key Takeaways
- NDC 00093-5062 (Cyltezo) is positioned in a rapidly growing biosimilar market segment.
- Prices are expected to decline 20-50% relative to originator prices over the next five years.
- Market share is rising but remains below the incumbent biologic, limiting revenue potential.
- Competition, regulatory developments, and payer policies will critically influence pricing and sales.
FAQs
-
What factors influence the pricing of biosimilars like Cyltezo?
Regulatory approval, payer negotiations, competition, and manufacturing costs.
-
How does Cyltezo's price compare to Humira?
It is generally priced 20-30% lower, with actual discounts varying by contract.
-
Are biosimilar prices expected to decline further?
Yes, as market saturation occurs and newer biosimilars enter.
-
What is Cyltezo's market share trend?
Growing steadily since approval, but still below 20% in the adalimumab segment.
-
What are the main drivers for biosimilar adoption?
Cost savings, payer incentives, and regulatory policies favoring substitution.
Sources
[1] IQVIA. "U.S. Biosimilar Market Data," 2023.
[2] Evaluate Pharma. "Biologics & Biosimilars Market Analysis," 2023.
[3] FDA. "Biologics License Application Approvals," 2017.
[4] Statista. "Humira (adalimumab) sales," 2023.
